Polyethylene Glycol Polyester Block Copolymers: Biocompatible Carriers for Nanoparticulate Drug Delivery - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 72

40. Kim, S. Y., Shin, I. G., Lee, Y. M., Cho, C. S., and Sung, Y. K. (1998). Methoxy
poly(ethylene glycol) and epsilon-caprolactone amphiphilic block
copolymeric micelle containing indomethacin. II. Micelle formation
and drug release behaviours. J Control Release 51: 13-22.
41. Elhasi, S., Astaneh, R., and Lavasanifar, A. (2007). Solubilization of an
amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles.
Eur J Pharm Biopharm 65: 406-413.
42. Allen, C., Yu, Y., Maysinger, D., and Eisenberg, A. (1998).
Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles
as a novel drug delivery vehicle for neurotrophic agents FK506 and
L-685,818. Bioconjug Chem 9: 564-572.
43. Allen, C., Eisenberg, A., Mrsic, J., and Maysinger, D. (2000). PCL-b-PEO
micelles as a delivery vehicle for FK506: assessment of a functional
recovery of crushed peripheral nerve. Drug Deliv 7: 139-145.
44. Allen, C., Han, J., Yu, Y., Maysinger, D., and Eisenberg, A. (2000).
Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery
vehicle for dihydrotestosterone. J Control Release 63: 275-286.
45. Aliabadi, H. M., Mahmud, A., Sharifabadi, A. D., and Lavasanifar, A.
(2005). Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-
caprolactone) as vehicles for the solubilization and controlled delivery
of cyclosporine A. J Control Release 104: 301-311.
46. Emens, L. A., Kennedy, M. J., Fetting, J. H., Davidson, N. E., Garrett, E.,
and Armstrong, D. K. (2002). A phase I toxicity and feasibility trial
of sequential dose-dense induction chemotherapy with doxorubicin,
paclitaxel, and 5-fluorouracil followed by high dose consolidation for
high-risk primary breast cancer. Breast Cancer Res Treat 76: 145-156.
47. Tsutani, Y., Saeki, T., Aogi, K., Ohsumi, S., and Takashima, S. (2005).
Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m 2 )
in adjuvant chemotherapy for breast cancer. Gan To Kagaku Ryoho 32:
809-813.
48. Kosugi, S., Kanda, T., Nakagawa, S., Ohashi, M., Nishimaki, T., and
Hatakeyama, K. (2005). Efficacy and toxicity of fluorouracil, doxorubicin,
and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for
advanced esophageal carcinoma. Scand J Gastroenterol 40: 886-892.
49. Suzuki, F., et al . (2005). Induction of tumor-specific cytotoxicity and
apoptosis by doxorubicin. Anticancer Res 25: 887-893.
50. Formariz, T. P., Sarmento, V. H., Silva-Junior, A. A., Scarpa, M. V.,
Santilli, C. V., and Oliveira, A. G. (2006). Doxorubicin biocompatible
O/W microemulsion stabilized by mixed surfactant containing soya
phosphatidylcholine. Colloids Surf B Biointerfaces 51: 54-61.